Summary & Overview
HCPCS A9554: Iodine I-125 Sodium Iothalamate, Diagnostic Per-Dose
HCPCS Level II code A9554 represents iodine I-125 sodium iothalamate supplied for diagnostic use, billed per study dose up to 10 microcuries. As a specialized radiopharmaceutical, this code is relevant to nuclear medicine imaging and renal function studies, and its use affects billing for outpatient imaging centers, hospital radiology departments, and specialty clinics that handle radiolabeled tracers. Nationally, accurate coding of radiopharmaceuticals like A9554 supports appropriate claims processing, inventory tracking, and compliance with radiation safety billing practices.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context, typical sites of service, common billing modifiers, and payer coverage patterns where available. The publication also outlines benchmark considerations and policy-relevant points affecting reimbursement workflows for radiopharmaceutical diagnostic studies.
This summary delivers practical reference material for coding and billing teams, revenue cycle stakeholders, and clinical program managers who oversee nuclear medicine services, enabling clearer alignment between clinical use and claims reporting.
Billing Code Overview
HCPCS Level II code A9554 describes iodine I-125 sodium iothalamate used for diagnostic studies, billed per study dose, up to 10 microcuries. This product is employed as a radiopharmaceutical diagnostic agent when a labeled iothalamate tracer is needed to evaluate renal function or perform radiolabeled agent studies.
-
Service type: Diagnostic radiopharmaceutical administration for nuclear medicine studies
-
Typical site of service: Hospital outpatient departments, nuclear medicine clinics, and specialized imaging centers equipped for radiopharmaceutical handling and diagnostic renal studies
Clinical & Coding Specifications
Clinical Context
A typical patient scenario involves an adult referred for a diagnostic renal nuclear medicine clearance study using iodinated radiopharmaceuticals. A 62-year-old patient presents with suspected decreased renal function after laboratory creatinine rise and asymmetric kidney size on ultrasound. The ordering nephrologist requests a quantitative renal cortical scintigraphy study using Iodine I-125 sodium iothalamate to assess glomerular filtration rate (GFR) per study dose up to 10 microcuries. The clinical workflow: the patient checks in at an outpatient nuclear medicine or radiology clinic; technologist verifies indications, allergies, and pregnancy status; baseline vitals are obtained. The radiopharmacy prepares the A9554 study dose and documents activity. The technologist administers the radiopharmaceutical intravenously, performs timed imaging and sample collection per protocol, and records injection time and residual dose. Images and quantitative measurements are processed; the interpreting nuclear medicine physician (or radiologist) reviews results and issues a report to the referring provider. Billing uses HCPCS Level II code A9554 for the study dose, alongside facility and professional services billed per usual CPT and institutional billing practice.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 |